DRAFT landscape of COVID-19 candidate vaccines

Metabolites/Chemicals-IVD

Alzheimer’s Disease (AD) Diagnostics

Bone metabolism & osteoporosis Diagnostics

Monkeypox virus (MPV) antigen & antibody

SARS-CoV-2 Solution

Bovine/Cattle Diagnostics Solution

Diagnostic Cancer

Diagnostic Infectious Disease

Diagnostic Inflammation/ Autoimmune/ Inflammatory Disease

Diagnostic Cardiovascular Disease

Diagnostic Liver Diseases

Diagnostic Lung Injury

Diagnostic Kidney Function (renal damages)

Diagnostic Gastric Disease

Diagnostic Thyroid Diseases

Diagnostic Bowel Disease

Diagnostic Fertility

Diagnostic Diabetes Diseases

Diagnostic Metabolic Disease

Diagnostic Hormone Disorders

Diagnostic Vitamin Deficiency

Diagnostic Fibrinogen Disorders

Diagnostic Neurodegenerative Diseases

Diagnostic Epilepsy

Diagnostic Pain

Diagnostic Multiple Disease

Diagnostic Biology

Diagnostic antibodies and antigens for Companion Animal disease testing

● Dog/Canine

● Cat/Feline

● Rabbit

Diagnostic antibodies and antigens for Swine disease testing

Diagnostic antibodies and antigens for Avian disease testing

Diagnostic antibodies and antigens for Multiple animal disease testing

Diagnostic antibodies and antigens for Ruminant disease testing

● Bovines/Cattle

● Ovines/Sheep

● Caprine/Goat

● Deer

Diagnostic antibodies and antigens for infectious and non-infectious  Equine/Horse disease testing

Diagnostic antibodies and antigens for Fish disease testing

Antibiotics

Food Safety

Agricultural

Allergen

Mycotoxins

Drugs of Abuse

Toxic Heavy Metal

Hormones

Chemicals

Vitamins

Amino Acids

Cell Therapy and Gene Therapy News

Gene Therapy Technical Articles

Technical Resources

How to order

How to pay

Product FAQs

SOCAIL MEDIA

137 candidate vaccines in clinical evaluation

ID Vaccine platform acronym Vaccine platform description Type of candidate vaccine  Route of administration Developers  Phase Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 Phase 4
1 IV Inactivated virus CoronaVac;  SARS-CoV-2 vaccine (inactivated) IM Sinovac Research and Development Co., Ltd Phase 4 NCT04383574 NCT04754698** NCT04456595 NCT04756830
Study Report Study Protocol NCT04747821
NCT04352608 NCT04508075 NCT04775069
NCT04551547  NCT04582344
Study Report NCT04617483
Study Report NCT04651790
2 IV Inactivated virus Inactivated SARS-CoV-2 vaccine (Vero cell) IM Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological Products  Phase 3 ChiCTR2000031809 ChiCTR2000034780
ChiCTR2000039000
NCT04510207 *
Interim Report NCT04612972
3 IV Inactivated virus Inactivated SARS-CoV-2 vaccine (Vero cell) IM Sinopharm  + China National Biotec Group Co + Beijing Institute of Biological Products Phase 3 ChiCTR2000032459 NCT04560881
Study Report NCT04510207*
4 VVnr Viral vector (Non-replicating) ChAdOx1-S – (AZD1222) (Covishield) IM AstraZeneca + University of Oxford Phase 4 PACTR202005681895696 PACTR202006922165132 NCT04686773 NCT04400838 ISRCTN89951424 NCT04760132
2020-001072-15 Study Report NCT04516746 NCT04775069
Interim Report ISRCTN69254139 Study Report NCT04540393
NCT04568031 Study Report NCT04536051
Study Report Study Report EUCTR2020-005226-28-DE
NCT04444674 Study Report
NCT04324606 CTRI/2020/08/027170 Study Report
Study Report ISRCTN69254139
Study Report
Study Report
NCT04684446
ISRCTN15638344
NCT04760730
5 VVnr Viral vector (Non-replicating) Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) IM  CanSino Biological Inc./Beijing Institute of Biotechnology Phase 3 ChiCTR2000030906 ChiCTR2000031781 NCT04526990
NCT04313127 NCT04398147 NCT04566770 NCT04540419
NCT04568811 NCT04341389
NCT04552366
Study Report Study Report
6 VVnr Viral vector (Non-replicating) Gam-COVID-Vac  Adeno-based (rAd26-S+rAd5-S) IM Gamaleya Research Institute ; Health Ministry of the Russian Federation Phase 3 NCT04436471 NCT04530396
Study Report
NCT04437875 NCT04564716
NCT04713488 NCT04587219 NCT04642339
Study Report NCT04640233 NCT04656613
NCT04760730 NCT04741061
7 VVnr Viral vector (Non-replicating) Ad26.COV2.S IM Janssen Pharmaceutical Phase 3 NCT04509947 NCT04436276 EUCTR2020-002584-63-DE NCT04505722
Study Report NCT04535453 Study Report
Study Report NCT04765384 NCT04614948
8 PS Protein subunit SARS-CoV-2 rS/Matrix M1-Adjuvant (Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M) IM Novavax Phase 3 NCT04368988  NCT04533399 NCT04611802
Study Report EUCTR2020-004123-16-GB
Study Report  NCT04583995
9 RNA RNA based vaccine mRNA -1273 IM Moderna + National Institute of Allergy and Infectious Diseases (NIAID) Phase 4 NCT04283461 NCT04677660 NCT04405076 NCT04649151 NCT04470427 NCT04760132
Interim Report NCT04712110 Study Report Study Report
Study Report NCT04761822
10 RNA RNA based vaccine BNT162 (3 LNP-mRNAs ) IM  Pfizer/BioNTech  + Fosun Pharma  Phase 4 NCT04523571 2020-001038-36 NCT04649021 NCT04754594 NCT04368728 NCT04760132
Study Report NCT04588480 NCT04761822 Study Report EUCTR2021-000412-28-BE
ChiCTR2000034825  NCT04380701 Study Report EUCTR2021-000412-28-BE
Study Report NCT04713553 NCT04780659
NCT04537949 NCT04775069
EUCTR2020-003267-26-DE
Study Report
11 PS Protein subunit Recombinant SARS-CoV-2 vaccine (CHO Cell)  IM Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences Phase 3 NCT04445194  NCT04550351 NCT04466085
ChiCTR2000035691  Study Report NCT04646590
 NCT04636333
12 RNA RNA based vaccine CVnCoV Vaccine IM CureVac AG Phase 3 NCT04449276  NCT04515147 NCT04652102 NCT04674189
PER-054-20
13 IV Inactivated virus SARS-CoV-2 vaccine (vero cells) IM Institute of Medical Biology + Chinese Academy of Medical Sciences Phase 3 NCT04470609 NCT04659239
NCT04412538
Study Report
14 IV Inactivated virus QazCovid-in® – COVID-19 inactivated vaccine IM Research Institute for Biological Safety Problems, Rep of Kazakhstan Phase 3 NCT04530357 NCT04691908
15 DNA DNA based vaccine INO-4800+electroporation ID  Inovio Pharmaceuticals + International Vaccine Institute + Advaccine (Suzhou) Biopharmaceutical Co., Ltd  Phase 2/3 NCT04336410 NCT04447781 ChiCTR2000040146  NCT04642638
Study Report
ChiCTR2000038152 
16 DNA DNA based vaccine AG0301-COVID19 IM AnGes + Takara Bio + Osaka University Phase 2/3 NCT04463472 NCT04655625
NCT04527081
jRCT2051200085
17 DNA DNA based vaccine nCov vaccine ID Zydus Cadila Phase 3 CTRI/2020/07/026352 CTRI/2020/07/026352
18 DNA DNA based vaccine GX-19 IM Genexine Consortium Phase 1/2 NCT04445389
NCT04715997
19 IV Inactivated virus Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) IM Bharat Biotech International Limited Phase 3 NCT04471519  NCT04641481; CTRI/2020/11/028976
Interim Study Report
Study Report
Study Report
CTRI/2020/07/026300
CTRI/2020/09/027674
20 PS Protein subunit KBP-COVID-19 (RBD-based) IM Kentucky Bioprocessing Inc. Phase 1/2 NCT04473690
21 PS Protein subunit  VAT00002:   SARS-CoV-2 vaccine formulation 1 with adjuvant 1 (S protein (baculovirus production) IM Sanofi Pasteur + GSK Phase 3 NCT04537208 NCT04762680 PACTR202011523101903**
22 RNA RNA based vaccine ARCT-021 IM Arcturus Therapeutics  Phase 2 NCT04480957 NCT04668339
NCT04728347
23 VLP Virus like particle RBD SARS-CoV-2 HBsAg VLP vaccine IM Serum Institute of India + Accelagen Pty + SpyBiotech Phase 1/2 ACTRN12620000817943
ACTRN12620001308987
24 IV Inactivated virus Inactivated SARS-CoV-2 vaccine (Vero cell)  IM Beijing Minhai Biotechnology Co Phase 2 NCT04758273 NCT04756323
25 VVnr Viral vector (Non-replicating)  GRAd-COV2 (Replication defective Simian Adenovirus (GRAd) encoding S) IM ReiThera + Leukocare + Univercells Phase 2/3 NCT04528641 EUCTR2020-005915-39-IT
26 VVnr Viral vector (Non-replicating)  VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine platform Oral Vaxart Phase 1 NCT04563702
27 VVnr Viral vector (Non-replicating) MVA-SARS-2-S IM University of Munich (Ludwig-Maximilians) Phase 1 NCT04569383
28 PS Protein subunit SCB-2019 + AS03 or CpG 1018 adjuvant plus Alum adjuvant  (Native like Trimeric subunit Spike Protein vaccine)   IM Clover Biopharmaceuticals Inc./GSK/Dynavax Phase 2/3 NCT04405908 NCT04672395
Study Report
Report
29 PS Protein subunit  COVAX-19® Recombinant spike protein + adjuvant IM Vaxine Pty Ltd.  Phase 1 NCT04453852
Protein subunit MF59 adjuvanted SARS-CoV-2 Sclamp vaccine  IM CSL Ltd. + Seqirus + University of Queensland Phase 1 Development has been suspended and the candidate vaccine has been removed from the landscape summary analysis
30 PS Protein subunit MVC-COV1901 (S-2P protein + CpG 1018) IM Medigen Vaccine Biologics + Dynavax + National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 NCT04487210 NCT04695652 
31 PS Protein subunit FINLAY-FR1 anti-SARS-CoV-2 Vaccine (RBD + adjuvant) IM Instituto Finlay de Vacunas  Phase 1/2 RPCEC00000338  RPCEC00000332
32 PS Protein subunit  FINLAY-FR-2 anti-SARS-CoV-2 Vaccine (RBD chemically conjugated to tetanus toxoid plus adjuvant) IM Instituto Finlay de Vacunas Phase 3 RPCEC00000340 RPCEC00000347 RPCEC00000354
33 PS Protein subunit EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) IM Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector” Phase 3 NCT04527575 NCT04780035
34 PS Protein subunit RBD (baculovirus production expressed in Sf9 cells)  Recombinant SARS-CoV-2 vaccine (Sf9 Cell)  IM West China Hospital + Sichuan University Phase 2 ChiCTR2000037518 ChiCTR2000039994 
NCT04530656  NCT04640402 
NCT04718467
35 PS Protein subunit IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides) SC University Hospital Tuebingen Phase 1 NCT04546841
36 PS Protein subunit UB-612 (Multitope peptide based S1-RBD-protein based vaccine) IM COVAXX + United Biomedical Inc Phase 2/3 NCT04545749 NCT04773067 NCT04683224
Viral vector (Replicating)  V591-001  – Measles-vector based (TMV-o38) IM Merck & Co. + Themis + Sharp & Dohme + Institute Pasteur + University of Pittsburgh Phase 1/2 NCT04497298 CT04498247  Development has been suspended and the candidate vaccines has been removed from the landscape summary analysis
NCT04569786
37 VVr Viral vector (Replicating) DelNS1-2019-nCoV-RBD-OPT1 (Intranasal flu-based-RBD ) IN University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmacy Phase 2 ChiCTR2000037782 ChiCTR2000039715
38 RNA RNA based vaccine LNP-nCoVsaRNA IM Imperial College London Phase 1 ISRCTN17072692
39 RNA RNA based vaccine SARS-CoV-2 mRNA vaccine (ARCoV) IM Academy of Military Science (AMS), Walvax Biotechnology and Suzhou Abogen Biosciences Phase 1 ChiCTR2000034112
ChiCTR2000039212 
40 VLP Virus like particle  Coronavirus-Like Particle COVID-19 (CoVLP) IM Medicago Inc. Phase 2/3 NCT04662697 NCT04636697
Study Report
41 VVr + APC Viral vector (Replicating) + APC Covid-19/aAPC vaccine.   The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune modulatory genes and the viral minigenes to the artificial antigen presenting cells (aAPCs). SC   Shenzhen Geno-Immune Medical Institute   Phase 1 NCT04299724
42 VVnr + APC Viral vector (Non-replicating) + APC LV-SMENP-DC vaccine.   Dendritic cells are modified with lentivirus vectors expressing Covid-19 minigene SMENP and immune modulatory genes. CTLs are activated by LV-DC presenting Covid-19 specific antigens. SC & IV Shenzhen Geno-Immune Medical Institute  Phase 1/2  NCT04276896
43 PS Protein subunit AdimrSC-2f (recombinant RBD +/- Aluminium) ND Adimmune Corporation  Phase 1 NCT04522089
44 DNA DNA based vaccine Covigenix VAX-001 – DNA vaccines + proteo-lipid vehicle (PLV) formulation IM Entos Pharmaceuticals Inc.  Phase 1 NCT04591184
45 DNA DNA based vaccine CORVax – Spike (S) Protein Plasmid DNA Vaccine  ID Providence Health & Services Phase 1 NCT04627675
46 RNA RNA based vaccine ChulaCov19 mRNA vaccine IM Chulalongkorn University Phase 1  NCT04566276
47 DNA DNA based vaccine bacTRL-Spike oral DNA vaccine Oral Symvivo Corporation Phase 1 NCT04334980
48 VVnr Viral vector (Non-replicating) Human Adenovirus Type 5: hAd5 S+N vaccine (S-Fusion + N-ETSD). E2b- Deleted Adeno. SC or Oral ImmunityBio, Inc. & NantKwest, Inc. Phase 1 NCT04591717
NCT04710303
NCT04732468
49 VVnr Viral vector (Non-replicating) COH04S1 (MVA-SARS-2-S) – Modified vaccinia ankara (sMVA) platform + synthetic SARS-CoV-2 IM City of Hope Medical Center + National Cancer Institute Phase 1 NCT04639466
Pre-clinical result
50 VVr Viral vector (Replicating) rVSV-SARS-CoV-2-S Vaccine IM Israel Institute for Biological Research  Phase 1/2 NCT04608305
51 VVr + APC Viral vector (Replicating) + APC Dendritic cell vaccine AV-COVID-19.  A vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF IM Aivita Biomedical, Inc. National Institute of Health Research and Development, Ministry of Health Republic of Indonesia Phase 1/2 NCT04690387 NCT04386252
NCT04685603
52 LAV Live attenuated virus COVI-VAC IN Codagenix/Serum Institute of India Phase 1 NCT04619628
53 PS Protein subunit CIGB-669 (RBD+AgnHB) IN  Center for Genetic Engineering and Biotechnology (CIGB)  Phase 1/2 RPCEC00000345
54 PS Protein subunit CIGB-66 (RBD+aluminium hydroxide) IM Center for Genetic Engineering and Biotechnology (CIGB)  Phase 1/2 RPCEC00000346
55 IV Inactivated Virus VLA2001 IM Valneva, National Institute for Health Research, United Kingdom Phase 1/2 NCT04671017
56 PS Protein subunit BECOV2 IM Biological E. Limited  Phase 1/2 CTRI/2020/11/029032
57 VVr Viral vector (Replicating) AdCLD-CoV19 (adenovirus vector)  IM Cellid Co., Ltd. Phase 1/2 NCT04666012
58 DNA DNA based vaccine GLS-5310 ID GeneOne Life Science, Inc. Phase 1/2 NCT04673149
59 PS Protein subunit Recombinant Sars-CoV-2 Spike protein, Aluminum adjuvanted IM Nanogen Pharmaceutical Biotechnology Phase 1/2 NCT04683484
60 PS Protein subunit Recombinant protein vaccine S-268019 (using Baculovirus expression vector system) IM Shionogi Phase 1/2 jRCT2051200092
Viral vector (Non-replicating) AdCOVID, Adenovirus-based platform expresses the receptor-binding domain (RBD) of the Sars-Cov-2 spike protein IN Altimmune, Inc. Phase 1 NCT04679909
61 VVnr Viral vector (Non-replicating) AZD2816; adenoviral vector ChAdOx platform and based on the Beta (B.1.351) variant IM AstraZeneca + University of Oxford Phase 2/3 NCT04973449
62 PS Protein subunit SARS-CoV-2-RBD-Fc fusion protein SC or IM University Medical Center Groningen + Akston Biosciences Inc. Phase 1/2 NCT04681092
63 IV Inactivated Virus ERUCOV-VAC, inactivated virus  IM Erciyes University Phase 1 NCT04691947
64 PS Protein subunit COVAC-1 and COVAC-2 sub-unit vaccine (spike protein) + SWE adjuvant  IM University of Saskatchewan Phase 1/2 NCT04702178
65 PS Protein subunit GBP510, a recombinant surface protein vaccine with adjuvant AS03 (aluminium hydroxide) IM SK Bioscience Co., Ltd. Phase 1/2 NCT04742738
NCT04750343
66 PS Protein subunit Razi Cov Pars, recombinant spike protein IM and IN Razi Vaccine and Serum Research Institute Phase 1 IRCT20201214049709N1
67 IV Inactivated Virus COVID-19 inactivated vaccine IM Shifa Pharmed Industrial Co Phase 1 IRCT20201202049567N1
68 PS Protein subunit MF59 adjuvanted SARS-CoV-2 Sclamp vaccine IM The University of Queensland Phase 1 NCT04495933
Study Report
69 DNA DNA based vaccine COVIGEN ID or IM University of Sydney, Bionet Co., Ltd Technovalia Phase 1 NCT04742842
70 DNA DNA based vaccine COVID-eVax, a candidate plasmid DNA vaccine of the Spike protein IM Takis + Rottapharm Biotech Phase 1/2 EudraCT:2020-003734-20
71 VVnr Viral vector (Non-replicating) BBV154, Adenoviral vector COVID-19 vaccine IN  Bharat Biotech International Limited Phase 1 NCT04751682
72 DNA DNA based vaccine COVID-eVax, A plasmid DNA vaccine targeted Spike protein production IM Takis and Rottapharm Biotech  Phase 1/2 EUCTR2020-003734-20-IT
73 RNA RNA based vaccine PTX-COVID19-B, mRNA vaccine IM Providence Therapeutics Phase 1 NCT04765436
74 VVr Viral vector (Replicating) NDV-HXP-S, Newcastle disease virus (NDV) vector expressing the spike protein of SARS-CoV-2, with or without the adjuvant CpG 1018 IM Mahidol University; The Government Pharmaceutical Organization (GPO); Icahn School of Medicine at Mount Sinai Phase 1/2 NCT04764422
75 RNA RNA based vaccine  CoV2 SAM (LNP) vaccine.  A self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform + Spike antigen IM GlaxoSmithKline Phase 1 NCT04758962
76 VLP Virus like particle VBI-2902a.  An enveloped virus-like particle (eVLP) of SARS-CoV-2 spike (S) glycoprotein and aluminum phosphate adjuvant. IM VBI Vaccines Inc. Phase 1/2 NCT04773665
77 PS Protein subunit SK SARS-CoV-2 recombinant protein subunit vaccine (NBP2001) + adjuvanted with alum. IM SK Bioscience Co., Ltd. Phase 1 NCT04760743
78 VVnr Viral vector (Non-replicating) Chimpanzee Adenovirus serotype 68 (ChAd) and self-amplifying mRNA (SAM) vectors expressing spike alone, or spike plus additional SARS-CoV-2 T cell epitopes. IM Gritstone Oncology Phase 1 NCT04776317
79 RNA RNA based vaccine mRNA-1273.351.  A lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized S protein of the SARS-CoV-2 B.1.351 variant. IM Moderna + National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 NCT04785144
80 PS Protein subunit SpFN (spike ferritin nanoparticle) uses spike proteins with a liposomal formulation QS21 (ALFQ) adjuvant. IM Walter Reed Army Institute of Research (WRAIR) Phase 1 NCT04784767
81 PS Protein subunit EuCorVac-19; A spike protein using the recombinant protein technology and with an adjuvant. IM EuBiologics Co.,Ltd Phase 1/2 NCT04783311
82 LAV Live attenuated virus MV-014-212, a live attenuated vaccine that expresses the spike (S) protein of SARS-CoV-2 IN Meissa Vaccines, Inc. Phase 1 NCT04798001
83 RNA RNA based vaccine MRT5500, an mRNA vaccine candidate IM Sanofi Pasteur and Translate Bio Phase 1/2 NCT04798027
84 VLP Virus like particle SARS-CoV-2 VLP Vaccine IM The Scientific and Technological Research Council of Turkey Phase 1 NCT04818281
85 PS Protein subunit ReCOV: Recombinant two-component spike and RBD protein COVID-19 vaccine (CHO cell). IM Jiangsu Rec-Biotechnology Phase 1 NCT04818801
86 RNA RNA based vaccine DS-5670a, mRNA vaccine IM Daiichi Sankyo Co., Ltd. Phase 1/2 NCT04821674
87 IV Inactivated Virus Inactivated COVID-19 vaccine IM Kocak Farma Phase 1 NCT04838080
88 VVnr Viral vector (Non-replicating) COVIVAC. Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein +/- adjuvant CpG 1018 IM Institute of Vaccines and Medical Biologicals Vietnam Phase 1/2 NCT04830800
89 VVnr Viral vector (Non-replicating) SC-Ad6-1 Adneviral vector vaccine IM Tetherex Pharmaceuticals Corporation Phase 1 NCT04839042
90 VLP Virus like particle ABNCoV2 capsid virus-like particle (cVLP) +/- adjuvant MF59 IM Radboud University Phase 1 NCT04839146
91 PS Protein subunit Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) IM Guangdong Provincial Center for Disease Control and Prevention/Gaozhou Center for Disease Control and Prevention Phase 2 ChiCTR2100045108 ChiCTR2100045107
92 RNA RNA based vaccine HDT-301: Self-replicating mRNA vaccine formulated as a lipid nanoparticle. IM SENAI CIMATEC Phase 1 NCT04844268
93 IV Inactivated Virus Adjuvanted inactivated vaccine against SARS-CoV-2 SC The Scientific and Technological Research Council of Turkey (TÜBITAK) Phase 1 NCT04866069
94 RNA RNA based vaccine mRNA-1283 IM ModernaTX, Inc. Phase 1 NCT04813796
95 PS Protein subunit Recombinant SARS-CoV-2 Vaccine (CHO cell) IM National Vaccine and Serum Institute, China Phase 1/2 NCT04869592
96 RNA RNA based vaccine EXG-5003; a temperature-sensitive self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein. ID Elixirgen Therapeutics, Inc Phase 1/2 NCT04863131
97 IV Inactivated Virus Inactivated COVID-19 vaccine IM Elixirgen Therapeutics, IncKM Biologics Co., Ltd. Phase 1/2 jRCT2071200106
98 IV Inactivated Virus Live recombinant Newcastle Disease Virus (rNDV) vector vaccine IM or IN Laboratorio Avi-Mex Phase 1 NCT04871737
99 RNA RNA based vaccine mRNA COVID-19 vaccine IM Shanghai East Hospital and Stemirna Therapeutics Phase 1 ChiCTR2100045984
100 PS Protein subunit CoVepiT vaccine: SARS-CoV-2 multi-target peptide vaccine (targeting Spike, M, N, and several non-structural proteins) SC OSE Immunotherapeutics Phase 1 NCT04885361
101 VVnr Viral vector (Non-replicating) Modified Vaccinia Virus Ankara (MVA) vector expressing a stabilized SARS-CoV-2 spike protein IM German Center for Infection Research Phase 1/2 NCT04895449
102 PS Protein subunit CoV2-OGEN1, protein-based vaccine Oral VaxForm Phase 1 NCT04893512
103 PS Protein subunit QazCoVac-P – COVID-19 Subunit Vaccine IM Research Institute for Biological Safety Problems Phase 1/2 NCT04930003
104 RNA RNA based vaccine LNP-nCOV saRNA-02 vaccine; Self-amplifying RNA (saRNA) encapsulated in lipid nanoparticles (LNP) IM MRC/UVRI and LSHTM Uganda Research Unit Phase 1 NCT04934111
105 RNA RNA based vaccine mRNA-1273.211. A multivalent booster candidate combining mRNA-1273 plus mRNA-1273.351. IM ModernaTX, Inc. Phase 2/3 NCT04927065
106 PS Protein subunit RBD protein recombinant SARS-CoV-2 vaccine IM Bagheiat-allah University of Medical Sciences Phase 1 IRCT20210620051639N1
107 PS Protein subunit Baiya SARS-CoV-2 VAX1, a plant-based subunit vaccine(RBD-Fc + adjuvant) IM Baiya Phytopharm Co., Ltd. Phase 1 NCT04953078
108 PS Protein subunit SCB-2020S, an adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from B.1.351 variant) IM Clover Biopharmaceuticals AUS Pty Ltd Phase 2 NCT04950751 **
109 VVnr Viral vector (Non-replicating) PIV5 vector that encodes the SARS-CoV-2 spike protein IM CyanVac LLC Phase 1 NCT04954287
110 PS Protein subunit 202-CoV; SARS-CoV-2 spike trimer protein + adjuvant, CpG7909. IM Shanghai Zerun Biotechnology + Walvax Biotechnology + CEPI Phase 1 NCT04982068 NCT04990544
111 DNA DNA based vaccine AG0302-COVID19 IM AnGes, Inc Phase 1/2 NCT04993586
112 PS Protein subunit Recombinant protein RBD fusion dimer adjuvanted vaccine (COVID-19 Vaccine Hipra) IM Laboratorios Hipra, S.A. Phase 1/2 NCT05007509
113 PS Protein subunit Versamune-CoV-2FC vaccine, recombinant S1 antigen NR Hospital do Coracao Phase 1/2 NCT05016934
114 RNA RNA based vaccine ARCT-154 mRNA Vaccine IM Arcturus Therapeutics, Inc. Phase 2/3 NCT05037097 NCT05012943
115 NA PRNA based vaccine ARCT-165 mRNA Vaccine IM Arcturus Therapeutics, Inc. Phase 1/2 NCT05037097
116 NA PRNA based vaccine ARCT-021 mRNA Vaccine IM Arcturus Therapeutics, Inc. Phase 1/2 NCT05037097
117 PS Protein subunit SII B.1.351 + Matrix-M1 adjuvant, a monovalent SII SARS-CoV-2 B.1.351 (Beta) variant vaccine IM Novavax Phase 1/2 NCT05029856
118 PS Protein subunit SII Bivalent + Matrix-M1 adjuvant, a bivalent SII vaccine containing antigen for both the ancestral strain and B.1.351 (Beta) variant of SARS-CoV-2 IM Novavax Phase 1/2 NCT05029857
119 PS Protein subunit SII B.1.617.2 + Matrix-M1 adjuvant, a monovalent SII SARS-CoV-2 B.1.617.2 (Delta) variant vaccine IM Novavax Phase 1/2 NCT05029858
120 VVnr Viral vector (Non-replicating) AAV5-RBD-S vaccine (BCD-250), A recombinant Adenovirus-Associated viral Vector (AAV-5) encoding spike protein IM Biocad Phase 1/2 NCT05037188
121 PS Protein subunit SCTV01C. A Bivalent Recombinant Trimeric S Protein vaccine against SARS-CoV-2 Variants IM Sinocelltech Ltd. Phase 2/3 NCT05043311
122 IV Inactivated Virus Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) IM Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products Phase 1/2 NCT05046548
123 DNA DNA based vaccine Plasmid DNA vaccine SCOV1 + SCOV2. COVIDITY ID/IM Scancell Ltd Phase 1 NCT04982068
124 BacAg-SpV Bacterial antigen-spore expression vector COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores Oral DreamTec Research Limited NA
125 DNA DNA based vaccine VB10.2129, a DNA plasmid vaccine, encoding the receptor binding domain (RBD) IM Vaccibody AS Phase 1/2 NCT05069623
126 DNA DNA based vaccine VB10.2210, DNA plasmid vaccine, encodes multiple immunogenic and conserved T cellepitopes spanning multiple antigens across the SARS-CoV-2 genome. IM Vaccibody AS Phase 1/2 NCT05069623
127 ps Protein subunit SARS-CoV-2 Protein Subunit Recombinant Vaccine IM Bio Farma Phase 1/2 NCT05067894
128 PS Protein subunit PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine IM Yisheng Biopharma Phase 1 ACTRN12621001009808
129 DNA DNA based vaccine SARS-CoV-2 DNA vaccine (delivered IM followed by electroporation) IM The University of Hong Kong; Immuno Cure 3 Limited Phase 1 NCT05102643
131 VVnr Viral vector (Non-replicating) Ad5-triCoV/Mac or ChAd-triCoV/Mac, new experimental adenovirus-based vaccines expressing SARS-CoV-2 spike, nucleocapsid and RNA polymerase proteins AE McMaster University Phase 1 NCT05094609
132 PS Protein subunit PepGNP-SARSCoV2, A CD8 T-cell priming adaptive vaccine composed of a Coronaviruses specific peptides mounted on a gold nanoparticle ID Emergex Vaccines Holding Limited Phase 1 NCT05113862
133 PS Protein subunit SARS-CoV-2 Vaccine (IN-B009) IM HK inno.N Corporation Phase 1 NCT05113849
134 VLP Virus like particle SARS-CoV-2 Vaccine LYB001, a receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide. IM Yantai Patronus Biotech Co., Ltd. Phase 1 NCT05125926 NCT05137444
135 IV Inactivated Virus Covi Vax, inactivated coronavirus vaccine IM National Research Centre, Egypt Phase 1 NCT05128721
136 RNA RNA based vaccine HDT-301 vaccine IM HDT Bio Phase 1 NCT05132907
137 RNA RNA based vaccine VLPCOV-01, self-amplifying RNA vaccine against the coronavirus IM VLP Therapeutics Japan GK Phase 1 jRCT2071210067

194 candidate vaccines in preclinical evaluation

ID Vaccine platform acronym Vaccine platform description Type of candidate vaccine Coronavirus target Same platform for non-Coronavirus candidates Developers
1 DNA DNA based vaccine DNA, engineered vaccine inserts compatible with multiple delivery systems SARS-CoV-2 and Sarbeco-CoV DIOSynVax Ltd + University of Cambridge
2 DNA DNA based vaccine DNA vaccine SARS-CoV2 Ege University
3 DNA DNA based vaccine DNA plasmid vaccine RBD&N SARS-CoV2 Scancell/University of Nottingham/ Nottingham Trent University
4 DNA DNA based vaccine DNA with electroporation SARS-CoV2 Karolinska Institute / Cobra Biologics (OPENCORONA Project)
5 DNA DNA based vaccine DNA with electroporation SARS-CoV2 Chula Vaccine Research Center
6 DNA DNA based vaccine Plasmid DNA, Needle-Free Delivery SARS-CoV2 SARS Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet
7 DNA DNA based vaccine DNA plasmid vaccine S,S1,S2,RBD &N SARS-CoV2 National Research Centre, Egypt
8 DNA DNA based vaccine DNA vaccine SARS-CoV2 BioNet Asia
9 DNA DNA based vaccine msDNA vaccine SARS-CoV2 Mediphage Bioceuticals/University of Waterloo
10 DNA DNA based vaccine DNA vaccine SARS-CoV2 Entos Pharmaceuticals
11 DNA DNA based vaccine DNA plasmids containing S-gene SARS-CoV2 Biosun Pharmed
12 DNA DNA based vaccine DNA plasmid vaccine SARS-CoV2 Globe  Biotech Limited, Bangladesh
13 DNA DNA based vaccine Plasmid DNA, nanostructured RBD SARS-CoV2 National institute of Chemistry, Slovenia
14 DNA DNA based vaccine DNA plasmid  vaccine encoding RBD SARS-CoV2 Vaccibody, Oslo Research Park, Norway
15 DNA DNA based vaccine DNA Immunostimulatory sequences SARS-CoV2 Inserm
16 DNA DNA based vaccine The 3 regions of SARS-Cov-2 Spike-protein: NTD, RBD and HR1-HR2  inserted into the plasmid of PcDNA3.1 (+). SARS-CoV2 Center of Genomics and Bioinformatics of Academy of Science of Republic of Uzbekistan
17 IV Inactivated virus Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018 SARS-CoV-2 Institute Butantan (Brazil) / Dynavax / PATH
18 IV Inactivated virus Inactivated + alum SARS-CoV2 JE, Zika KM Biologics
19 IV Inactivated virus Inactivated SARS-CoV2 Selcuk University
20 IV Inactivated virus SARS-CoV2 Osaka University/ BIKEN/ NIBIOHN
21 IV Inactivated virus Inactivated + CpG 1018 SARS-CoV2 Sinovac/Dynavax
22 IV Inactivated virus Inactivated + CpG 1018 SARS-CoV2 Valneva/Dynavax
23 IV Inactivated virus Inactivated whole virus SARS-CoV2 National Research Centre, Egypt
24 IV Inactivated virus Inactivated SARS-CoV2 MMR, IPV Milad Pharmaceutics Co.
25 IV Inactivated virus Inactivated SARS-CoV2 MMR, IPV Zista Kian Azma Co.
26 IV Inactivated virus Inactivated + alum SARS-CoV2 Paya Fan Yakhte Alborz – Osveh / Iran
27 IV Inactivated virus Inactivated vaccine (Vero Cell)  SARS-CoV2 Airlangga University, Indonesia in partnership with Biotis Pharmaceuticals Indonesia
28 LAV Live attenuated virus Codon deoptimized live attenuated vaccines SARS-CoV2 Mehmet Ali Aydinlar University / Acıbadem Labmed Health Services A.S.
29 LAV Live attenuated virus Codon deoptimized live attenuated vaccines SARS-CoV2 Indian Immunologicals Ltd/Griffith University
30 LABV Live attenuated bacterial vector Live attenuated bacterial (Pertussis) Vector SARS-CoV2 Institut Pasteur Lille, Inserm
31 LABV Live attenuated bacterial vector Live attenuated bacterial vector SARS-CoV2 ALtraBio, TheRex
32 VVnr Viral vector (Non-replicating) Sendai virus vector SARS-CoV2 ID Pharma
33 VVnr Viral vector (Non-replicating) Sendai virus vector SARS-CoV2 RSV, CMV Max Planck Institute for Biochemstry/vir4vac, Germany
34 VVnr Viral vector (Non-replicating) Adenovirus-based SARS-CoV2 Ankara University
35 VVnr Viral vector (Non-replicating) Adeno-associated virus vector (AAVCOVID) SARS-CoV2 Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis
36 VVnr Viral vector (Non-replicating) MVA encoded VLP SARS-CoV2 LASV, EBOV, MARV, HIV GeoVax/BravoVax
37 VVnr Viral vector (Non-replicating) MVA-S SARS-CoV2 IDIBAPS-Hospital Clinic, Spain
38 VVnr Viral vector (Non-replicating) Adeno5-based SARS-CoV2 Erciyes University
39 VVnr Viral vector (Non-replicating) Ad5 S (GREVAX™ platform) SARS-CoV2 MERS Greffex
40 VVnr Viral vector (Non-replicating) Oral Ad5 S SARS-CoV2 Zika, VZV, HSV-2 and Norovirus Stabilitech Biopharma Ltd
41 VVnr Viral vector (Non-replicating) Adenovirus-based  +  HLA-matched peptides Pan-Corona Valo Therapeutics Ltd
42 VVnr Viral vector (Non-replicating) MVA expressing structural proteins SARS-CoV2 Multiple candidates Centro Nacional Biotecnología (CNB-CSIC), Spain
43 VVnr Viral vector (Non-replicating) Parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein SARS-CoV2 MERS University of Georgia/University of Iowa
44 VVnr Viral vector (Non-replicating) Recombinant deactivated rabies virus containing S1 SARS-CoV2 HeV, NiV, EBOV, LASSA, CCHFV, MERS Bharat Biotech/Thomas Jefferson University
45 VVnr Viral vector (Non-replicating) Influenza A H1N1 vector SARS-CoV2 National Research Centre, Egypt
46 VVnr Viral vector (Non-replicating) Newcastle disease virus expressing the spike protein SARS-CoV2 Icahn School of Medicine at Mount Sinai
47 VVnr Viral vector (Non-replicating) Newcastle disease virus expressing membrane-anchored spike SARS-CoV2 Icahn School of Medicine at Mount Sinai
48 VVnr Viral vector (Non-replicating) Lentiviral Vector SARS-CoV2 Theravectys – Institut Pasteur
49 VVnr Viral vector (Non-replicating) Lentiviral Vector SARS-CoV2 AIOVA
50 VVnr Viral vector (Non-replicating) Lentiviral Vector Retro-VLP Particles SARS-CoV2 Sorbonne University
51 VVnr Viral vector (Non-replicating) Ad 5 vector for intranasal administration SARS-CoV2 University of Helsinki & University of Eastern Finland
52 VVnr Viral vector (Non-replicating) Oral vaccine platform SARS-CoV2 InfA, CHIKV, LASV, NORV; EBOV, RVF, HBV, VEE Vaxart
53 VVnr Viral vector (Non-replicating) Recombinant Adenovirus Vector (Type 5) + Spike protein of SARS-CoV-2 SARS-CoV2 Pasteur Institute / Iran
54 VVnr Viral vector (Non-replicating) Recombinant Adenovirus Vector (ChAdOx1) + Spike protein of SARS-CoV-2 SARS-CoV2 Pasteur Institute / Iran
55 VVnr Viral vector (Non-replicating) Adenovirus-based SARS-CoV2 Home Iman Zist Fanavar
56 VVnr Viral vector (Non-replicating) Chimpanzee adenovirus vector expressing the RBD-dimer without adjuvant SARS-CoV2 Chengdu Kanghua Biological Products Co., Ltd.
57 PS Protein subunit RBD protein delivered in mannose-conjugated chitosan nanoparticle SARS-CoV2 Ohio State University / Kazakh National Agrarian University
58 PS Protein subunit Recombinant spike protein with Essai O/W 1849101 adjuvant SARS-CoV2 Kazakh National Agrarian University
59 PS Protein subunit Peptides SARS-CoV2 Neo7Logic
60 PS Protein subunit Recombinant spike protein with Essai O/W 1849101 adjuvant SARS-CoV2 Kazakh National Agrarian University, Kazakhstan / National Scientific Center for Especially Dangerous Infections
61 PS Protein subunit Recombinant S protein SARS-CoV2 Max-Planck-Institute of Colloids and Interfaces
62 PS Protein subunit RBD protein (baculovirus production) + FAR-Squalene adjuvant SARS-CoV2 Multiple candidates Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH)
63 PS Protein subunit RBD-protein SARS-CoV2 Mynvax
64 PS Protein subunit Recombinant S protein SARS-CoV2 Izmir Biomedicine and Genome Center
65 PS Protein subunit Peptide + novel adjuvant SARS-CoV2 Bogazici University
66 PS Protein subunit S subunit intranasal liposomal formulation with GLA/3M052 adjs. SARS-CoV2 University of Virginia
67 PS Protein subunit S-Protein (Subunit) + Adjuvant, E coli and Insect vectors for expression/synthesis of the protein SARS-CoV2 Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria.
68 PS Protein subunit Protein Subunit S,N,M&S1 protein SARS-CoV2 National Research Centre, Egypt
69 PS Protein subunit Protein Subunit SARS-CoV2 University of San Martin and CONICET, Argentina
70 PS Protein subunit RBD protein fused with Fc of IgG + Adj. SARS-CoV2 Chulalongkorn University/GPO, Thailand
71 PS Protein subunit Capsid-like Particle SARS-CoV2 AdaptVac (PREVENT-nCoV consortium)
72 PS Protein subunit Drosophila S2 insect cell expression system VLPs SARS-CoV2 ExpreS2ion
73 PS Protein subunit Peptide antigens formulated in LNP SARS-CoV2 IMV Inc
74 PS Protein subunit S protein SARS-CoV2 WRAIR/USAMRIID
75 PS Protein subunit S protein +Adjuvant SARS-CoV2 Influenza National Institute of Infectious Disease, Japan/Shionogi/UMN Pharma
76 PS Protein subunit VLP-recombinant protein + Adjuvant SARS-CoV2 Osaka University/ BIKEN/  National Institutes of Biomedical Innovation, Japan
77 PS Protein subunit microneedle arrays S1 subunit SARS-CoV2 MERS Univ. of Pittsburgh
78 PS Protein subunit Peptide SARS-CoV2 Vaxil Bio
79 PS Protein subunit Adjuvanted protein subunit (RBD) SARS-CoV2 Biological E Ltd
80 PS Protein subunit Peptide SARS-CoV2 Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, BreastCA vaccine Flow Pharma Inc
81 PS Protein subunit S protein SARS-CoV2 AJ Vaccines
82 PS Protein subunit Ii-Key peptide SARS-CoV2 Influenza, HIV, SARS-CoV Generex/EpiVax
83 PS Protein subunit S protein SARS-CoV2 H7N9 EpiVax/Univ. of Georgia
84 PS Protein subunit Protein Subunit EPV-CoV-19 SARS-CoV2 EpiVax
85 PS Protein subunit gp-96 backbone SARS-CoV2 NSCLC, HIV, Malaria, Zika Heat Biologics/Univ. Of Miami
86 PS Protein subunit Subunit vaccine SARS-CoV2 FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
87 PS Protein subunit S1 or RBD protein SARS-CoV2 SARS Baylor College of Medicine
88 PS Protein subunit Subunit protein, plant produced SARS-CoV2 iBio/CC-Pharming
89 PS Protein subunit Recombinant protein, nanoparticles (based on S-protein and other epitopes) SARS-CoV2 Saint-Petersburg scientific research institute of vaccines and serums
90 PS Protein subunit Cross-reactive T-cell recombinant vaccine based on SARS-CoV-2 nucleoprotein (N) expressed in E.coli SARS-CoV2 various (cross-immunity) FSUE SPbSRIVS FMBA of Russia (St. Petersburg Institute of Vaccines)
91 PS Protein subunit COVID-19 XWG-03 truncated S (spike) proteins SARS-CoV2 HPV Innovax/Xiamen Univ./GSK
92 PS Protein subunit Adjuvanted microsphere peptide SARS-CoV2 VIDO-InterVac, University of Saskatchewan
93 PS Protein subunit Synthetic Long Peptide Vaccine candidate for S and M proteins SARS-CoV2 OncoGen
94 PS Protein subunit Oral  E. coli-based protein expression system of S and N proteins SARS-CoV2 MIGAL Galilee Research Institute
95 PS Protein subunit Nanoparticle vaccine SARS-CoV2 LakePharma, Inc.
96 PS Protein subunit Plant-based subunit (RBD-Fc + Adjuvant) SARS-CoV2 Baiya Phytopharm/ Chula Vaccine Research Center
97 PS Protein subunit OMV-based vaccine SARS-CoV2 Flu A, Plague Quadram Institute Biosciences
98 PS Protein subunit OMV-based vaccine SARS-CoV2 BiOMViS Srl/Univ. of Trento
99 PS Protein subunit structurally modified spherical particles of the tobacco mosaic virus (TMV) SARS-CoV2 Rubella, Rotavirus Lomonosov Moscow State University
100 PS Protein subunit Spike-based SARS-CoV2 Hepatitis C University of Alberta
101 PS Protein subunit Recombinant S1-Fc fusion protein SARS-CoV2 AnyGo Technology
102 PS Protein subunit Recombinant protein SARS-CoV2 Yisheng Biopharma
103 PS Protein subunit Recombinant S protein in IC-BEVS (Viral vector vaccine (based on baculovirus expression system in insect cell line) SARS-CoV2 Vabiotech, Vietnam and University of Bristol, UK
104 PS Protein subunit Orally delivered, heat stable subunit SARS-CoV2 Applied Biotechnology Institute, Inc.
105 PS Protein subunit Peptides derived from Spike protein SARS-CoV2 Axon Neuroscience SE
106 PS Protein subunit Protein Subunit SARS-CoV2 MOGAM Institute for Biomedical Research, GC Pharma
107 PS Protein subunit RBD-based SARS-CoV2 Neovii/Tel Aviv University
108 PS Protein subunit Outer Membrane Vesicle (OMV)-subunit SARS-CoV2 Intravacc/Epivax
109 PS Protein subunit Spike-based (epitope screening) SARS-CoV2 ImmunoPrecise/LiteVax BV
110 PS Protein subunit Spiked-based SARS-CoV2 Nanografi Nano Technology, Middle East Technical University, Ankara University,
111 PS Protein subunit Recombinant spike with adjuvant SARS-CoV2 Iran
112 PS Protein subunit Recombinant S protein produced in BEVS SARS-CoV2 Tampere University
113 PS Protein subunit Protein Subunit Nanoformulated SARS-CoV2 Vaxinano, CEA, INRAE
114 PS Protein subunit Protein Subunit Adenoviral Carrier SARS-CoV2 CEA, CNRS
115 PS Protein subunit Protein DC-targeted epitopes SARS-CoV2 LinkinVax, VRI, Inserm
116 PS Protein subunit Soluble recombinant S protein produced in CHO cells SARS-CoV2 Center for Advanced Technologies, Uzbekistan
117 PS Protein subunit NYVAC-KC, attenuated vaccinia virus vector expressing SARS-CoV-2 Spike and other viral proteins SARS-CoV2 Arizona State University
118 PS Protein subunit Protein peptides with alum SARS-CoV2 Hacettepe University, Turkey
119 PS Protein subunit Recombinant Spike (S) proteins encoded by Baculoviruses in Insect cells SARS-CoV2 Marmara University, Turkey
120 PS Protein subunit Adjuvanted Peptides + Recombinant Spike Protein SARS-CoV2 Yıldız Technical University, Turkey
121 PS Protein subunit Development of recombinant protein based S1 and S2 (Spike) and nucleocapsid subunits vaccines using a plant expression vector. SARS-CoV2 Akdeniz University, Department of Agricultural Biotechnology, Antalya, Turkey
122 PS Protein subunit Recombinant Protein Vaccine SARS-CoV2 Ataturk University, Vaccine Research Center (Erzurum) and Health Institutes of Turkey (TUSEB)
123 PS Protein subunit Recombinant protein subunit vaccine SARS-CoV2 Pharmada Pharmaceuticals/TURKEY
124 PS Protein subunit Recombinant Spike Protein SARS-CoV2 CinnaGen Co
125 PS Protein subunit Recombinant SARS CoV-2 RBD Protein, Alum adjuvanted SARS-CoV2 Bio Farma + Baylor College Medicine
126 PS Protein subunit TerraCoV2 recombinant protein (stabilized pre-fusion spike protein) Wuhan B.1.351 (Beta) Oragenics Inc, in cooperation with NRC Canada and Biodextris, Inc
127 PS Protein subunit Multiple peptides fragments targeting (S, M, N) and (NSPs) SARS-CoV-2 proteins to induce T cell responses (CD8) SARS-CoV2 OSE immunotherapeutics
128 PS Protein subunit BD-COV-001 B.1.351 antigen encapsulated in polymersomes SARS-CoV2 ACM Biosciences
129 PS Protein subunit Recombinant protein SARS-CoV2 Biosun Pharmed / Iran
130 PS Protein subunit Recombinant protein with hepatitis B VLP vector + Alum SARS-CoV3 Rahpouyan Fanavar Sadegh (RFS) / Iran
131 PS Protein subunit Recombinant Protein (Leishmania host) SARS-CoV4 Zist Salak / Iran
132 BVr Bacterial vector (Replicating) Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD SARS-CoV2 Multiple candidates Farmacológicos Veterinarios SAC (FARVET SAC)
133 VVr Viral vector (Replicating) YF17D Vector SARS-CoV2 KU Leuven
134 VVr Viral vector (Replicating) Measles Vector SARS-CoV2 Cadila Healthcare Limited
135 VVr Viral vector (Replicating) Measles Vector SARS-CoV2 FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
136 VVr Viral vector (Replicating) Measles Virus (S, N targets) SARS-CoV2 Zika, H7N9, CHIKV DZIF – German Center for Infection Research/CanVirex AG
137 VVr Viral vector (Replicating) Horsepox vector expressing S protein SARS-CoV2 Smallpox, Monkeypox Tonix Pharma/Southern Research
138 VVr Viral vector (Replicating) Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal) SARS-CoV2 Influenza BiOCAD and IEM
139 VVr Viral vector (Replicating) Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal) SARS-CoV2 Influenza FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
140 VVr Viral vector (Replicating) Attenuated Influenza expressing an antigenic portion of the Spike protein SARS-CoV2 Influenza Fundação Oswaldo Cruz and Instituto Buntantan
141 VVr Viral vector (Replicating) Influenza vector expressing RBD SARS-CoV2 University of Hong Kong
142 VVr Viral vector (Replicating) Replication-competent VSV chimeric virus technology (VSVΔG) delivering the SARS-CoV-2 Spike (S) glycoprotein. SARS-CoV2 Ebola, Marburg, Lassa IAVI/Merck
143 VVr Viral vector (Replicating) Replicating VSV vector-based DC-targeting SARS-CoV2 University of Manitoba
144 VVr Viral vector (Replicating) VSV-S SARS-CoV2 HIV, MERS University of Western Ontario
145 VVr Viral vector (Replicating) VSV-S SARS-CoV2 Aurobindo
146 VVr Viral vector (Replicating) VSV vector SARS-CoV2 FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
147 VVr Viral vector (Replicating) M2-deficient single replication (M2SR) influenza vector SARS-CoV2 Influenza UW–Madison/FluGen/Bharat Biotech
148 VVr Viral vector (Replicating) Newcastle disease virus vector (NDV-SARS-CoV-2/Spike) SARS-CoV2 Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.
149 VVr Viral vector (Replicating) Avian paramyxovirus vector (APMV) SARS-CoV2 The Lancaster University, UK
150 VVr Viral vector (Replicating) Intranasal Newcastle disease virus vector (rNDV-LS1-FARVET) expressing RBD protein: rNDV-LS1-HN-RBD/SARS-CoV-2 SARS-CoV2 Multiple candidates Farmacológicos Veterinarios SAC (FARVET SAC)
151 VVr Viral vector (Replicating) Intranasal Newcastle disease virus vector (rNDV-LS1-FARVET) expressing S1 protein: rNDV-LS1-S1-F/SARS-CoV-2 SARS-CoV2 Multiple candidates Farmacológicos Veterinarios SAC (FARVET SAC)
152 RNA RNA based vaccine saRNA formulated in a NLC SARS-CoV2 Infectious Disease Research Institute/ Amyris, Inc.
153 RNA RNA based vaccine LNP-encapsulated mRNA encoding S SARS-CoV2 Max-Planck-Institute of Colloids and Interfaces
154 RNA RNA based vaccine Self-amplifying RNA SARS-CoV2 Gennova
155 RNA RNA based vaccine mRNA SARS-CoV2 Selcuk University
156 RNA RNA based vaccine LNP-mRNA SARS-CoV2 Translate Bio/Sanofi Pasteur
157 RNA RNA based vaccine LNP-mRNA SARS-CoV2 CanSino Biologics/Precision NanoSystems
158 RNA RNA based vaccine LNP-encapsulated mRNA  cocktail encoding VLP SARS-CoV2 Fudan University/ Shanghai JiaoTong University/RNACure Biopharma
159 RNA RNA based vaccine LNP-encapsulated mRNA encoding RBD SARS-CoV2 Fudan University/ Shanghai JiaoTong University/RNACure Biopharma
160 RNA RNA based vaccine Replicating Defective SARS-CoV-2 derived RNAs SARS-CoV2 Centro Nacional Biotecnología (CNB-CSIC), Spain
161 RNA RNA based vaccine LNP-encapsulated mRNA SARS-CoV2 MERS University of Tokyo/ Daiichi-Sankyo
162 RNA RNA based vaccine Liposome-encapsulated mRNA SARS-CoV2 BIOCAD
163 RNA RNA based vaccine Several mRNA candidates SARS-CoV2 RNAimmune, Inc.
164 RNA RNA based vaccine mRNA SARS-CoV2 FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
165 RNA RNA based vaccine mRNA SARS-CoV2 China CDC/Tongji University/Stermina
166 RNA RNA based vaccine mRNA in an intranasal delivery system SARS-CoV2 eTheRNA
167 RNA RNA based vaccine mRNA SARS-CoV2 Greenlight Biosciences
168 RNA RNA based vaccine mRNA SARS-CoV2 IDIBAPS-Hospital Clinic, Spain
169 RNA RNA based vaccine mRNA SARS-CoV2 Providence Therapeutics
170 RNA RNA based vaccine mRNA SARS-CoV2 Cell Tech Pharmed
171 RNA RNA based vaccine mRNA SARS-CoV2 ReNAP Co.
172 RNA RNA based vaccine D614G variant LNP-encapsulated mRNA SARS-CoV2 Globe Biotech Ltd
173 RNA RNA based vaccine Encapsulated mRNA SARS-CoV2 CEA
174 RNA RNA based vaccine Recombinant, prefusion stabilized SARS-CoV-2 Spike antigen SARS-CoV2 Medigen Vaccines Biologics Corp (MVC)/Vaxess Technologies (MIMIX)
175 RNA RNA based vaccine ZIP1642 is a self-amplifying RNA vaccine encapsulated in an LNP, which encodes for multiple antigens, including the Spike (S) protein. SARS-CoV2 Ziphius Vaccines and Ghent University
176 VLP Virus like particle VLP SARS-CoV2 Max Planck Institute for Dynamics of Complex Technical Systems
177 VLP Virus like particle Virus-like particle-based Dendritic Cell(DC)-targeting vaccine SARS-CoV2 University of Manitoba
178 VLP Virus like particle VLP SARS-CoV2 Bezmialem Vakif University
179 VLP Virus like particle Enveloped Virus-Like Particle (eVLP) SARS-CoV-2, SARS-CoV, & MERS-CoV CMV, GBM, Zika VBI Vaccines Inc.
180 VLP Virus like particle S protein integrated in HIV VLPs SARS-CoV2 IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing Centre/Grifols
181 VLP Virus like particle VLP + Adjuvant SARS-CoV2 Mahidol University/ The Government Pharmaceutical Organization (GPO)/Siriraj Hospital
182 VLP Virus like particle Virus-like particles,  lentivirus and baculovirus vehicles SARS-CoV2 Navarrabiomed, Oncoimmunology group
183 VLP Virus like particle Virus-like particle, based on RBD displayed on virus-like particles SARS-CoV2 Saiba GmbH
184 VLP Virus like particle ADDomerTM multiepitope display SARS-CoV2 Imophoron Ltd and Bristol University’s Max Planck Centre
185 VLP Virus like particle Unknown SARS-CoV2 Doherty Institute
186 VLP Virus like particle VLP SARS-CoV1, SARS-CoV2 OSIVAX
187 VLP Virus like particle eVLP SARS-CoV2 Malaria ARTES Biotechnology
188 VLP Virus like particle VLPs peptides/whole virus SARS-CoV2 Univ. of Sao Paulo
189 VLP Virus like particle VLPs produced in BEVS SARS-CoV2 Tampere University
190 VLP Virus like particle Plant derived VLP SARS-CoV2 Shiraz University
191 VLP Virus like particle Myxoma virus co-expressing S, M, N and E proteins SARS-CoV2 Arizona State University
192 VLP Virus like particle Plasmid driven production of virus -Like-Particles (VLPs) containing S, M, N and E proteins of SARS-CoV-2 SARS-CoV2 Arizona State University
193 VLP Virus like particle Virus Like Particle with RCB SARS-CoV2 Berna Biotech Pharma
194 Cell Cellular based vaccine Engineered human mesenchymal stem cells transfected with a plasmid expressing S and N-protein SARS-CoV2 Cell Tech Pharmed